All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...

The second cycle of negotiations will take place under President Donald Trump's administration. The U.S. government has said ...

AbbVie has surged 9.9% in the past month, outperforming the S&P 500’s 7.4% decline. Earnings estimates suggest a solid ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

Berenberg raised AbbVie’s price target from $165 to $195 while maintaining a Hold rating. The firm increased its estimates ...

Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...

While the stock rose 7% in 2024, that gain was split between a 318% rocket ride higher from where it ended 2023 (at $28.43) to its March 13 record close of $118.81, and the 74% plunge from there to ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...